Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Declines By 16.8%

Jasper Therapeutics, Inc. (NASDAQ:JSPR) was the recipient of a large decrease in short interest in February. As of February 28th, there was short interest totalling 2,080,000 shares, a decrease of 16.8% from the February 13th total of 2,500,000 shares. Based on an average daily trading volume, of 522,500 shares, the days-to-cover ratio is currently 4.0 days. Currently, 17.5% of the shares of the stock are short sold.

Hedge Funds Weigh In On Jasper Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Rhumbline Advisers boosted its position in shares of Jasper Therapeutics by 12.6% in the fourth quarter. Rhumbline Advisers now owns 14,761 shares of the company’s stock worth $316,000 after buying an additional 1,652 shares during the period. BNP Paribas Financial Markets boosted its holdings in Jasper Therapeutics by 208.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock worth $47,000 after acquiring an additional 1,698 shares during the period. Barclays PLC raised its stake in shares of Jasper Therapeutics by 13.6% during the fourth quarter. Barclays PLC now owns 18,334 shares of the company’s stock valued at $392,000 after purchasing an additional 2,188 shares during the period. Wellington Management Group LLP lifted its position in shares of Jasper Therapeutics by 13.9% during the fourth quarter. Wellington Management Group LLP now owns 27,069 shares of the company’s stock worth $579,000 after purchasing an additional 3,310 shares in the last quarter. Finally, Wells Fargo & Company MN grew its holdings in Jasper Therapeutics by 106.7% during the 4th quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock valued at $159,000 after purchasing an additional 3,828 shares in the last quarter. Institutional investors and hedge funds own 79.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on JSPR. JMP Securities reissued a “market outperform” rating and issued a $70.00 price target on shares of Jasper Therapeutics in a report on Monday, January 6th. Royal Bank of Canada reduced their target price on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a report on Thursday, January 9th. BMO Capital Markets initiated coverage on shares of Jasper Therapeutics in a report on Friday, December 6th. They set an “outperform” rating and a $63.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Jasper Therapeutics in a research note on Tuesday, March 11th. Finally, UBS Group started coverage on shares of Jasper Therapeutics in a research note on Thursday, February 13th. They issued a “buy” rating and a $38.00 target price for the company. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Jasper Therapeutics has an average rating of “Buy” and a consensus target price of $62.50.

Jasper Therapeutics Stock Performance

Jasper Therapeutics stock traded up $0.16 during midday trading on Thursday, reaching $5.35. The stock had a trading volume of 51,042 shares, compared to its average volume of 267,337. The stock’s 50-day simple moving average is $5.86 and its 200 day simple moving average is $15.49. Jasper Therapeutics has a twelve month low of $4.55 and a twelve month high of $31.01. The stock has a market capitalization of $80.37 million, a PE ratio of -1.14 and a beta of 2.23.

Jasper Therapeutics (NASDAQ:JSPR) last issued its earnings results on Thursday, February 27th. The company reported ($1.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.35). Equities analysts predict that Jasper Therapeutics will post -4.47 earnings per share for the current fiscal year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.